Trial Information

Summary: First or second line treatment for chronic lymphocytic leukemia (CLL) utilizing nipent, cytoxan and rituxan.

Inclusion:

  • Stage II, III, or IV CLL histologically or cytologically proven.
  • CT or MRI confirming a measurable tumor size (lymph node must be > 1 cm in its longest transverse diameter) or measurable splenomegaly or hepatomegaly.
  • Positive expression of CD5, CD20, and CD23.
  • Adequate cardiac function.
  • ECOG 0-2.

Exclusion:

  • Known HIV.
  • Prior chemotherapy for CLL.
  • Thyroid disease in which thyroid function cannot be maintained within the normal range without the use of medication.
  • More than one prior chemotherapy treatment.

For more information,

Contact:

Cathy Spears, RN, Director of Clinical Research
American Health Network of Indiana LLC, Oncology Division
1828 No. Illinois St
Indianapolis, IN 46202
Telephone: 317-833-1297
Email:

Profile Page: American Health Network of Indiana LLC, Oncology Division, Indianapolis, IN

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:44:34 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA